- Home
- IFRX vs INKT Comparison
IFRX vs INKT Comparison
Compare IFRX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IFRX | INKT |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 57.6M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IFRX | INKT |
|---|---|---|
| Price | $0.83 | $11.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $8.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 609.3K | 11.1K |
| Earning Date | 03-19-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,729.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,054.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $6.34 |
| 52 Week High | $2.77 | $76.00 |
Technical Indicators
Market Signals| Indicator | IFRX | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 38.68 |
| Support Level | $0.88 | $10.99 |
| Resistance Level | $1.01 | $12.90 |
| Average True Range (ATR) | 0.09 | 0.48 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 8.87 | 7.33 |
Price Performance
Historical ComparisonAbout IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.